Pharmacogenomic screening can identify patients with gene variants that predispose them
to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of …

The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays a
key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4–5% of the …

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is
gaining importance as predictors of fluoropyrimidine-associated toxicity. The …

Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-
limiting enzyme responsible for fluoropyrimidine (FP) catabolism. DPYD gene variants …

Among cancer patients treated with fluoropyrimidines, 10–40% develop severe toxicity.
Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD …

Fluoropyrimidines (FP; 5‐fluorouracil, capecitabine, and tegafur) are a commonly prescribed
class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 …

Aim: To evaluate toxicity risk in carriers of four DPYD variants using an institutional genetic
repository. Materials & methods: Of over 65,000 patients in the repository, 582 were …

Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD)
encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to …

DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical
care. Without phasing information (ie, allelic location of variants), current genotype-based …

In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe
fluoropyrimidine‐related toxicity. Extensively clinically validated DPYD genotyping tests are …